Antithrombotic drugs market size to grow by USD 23,199.94 million from 2022 to 2027: The growing prevalence of coagulation disorders drives growth - Technavio

NEW YORK, Aug. 8, 2023 /PRNewswire/ -- The global antithrombotic drugs market size is estimated to increase by USD 23,199.94 million from 2022 to 2027. The market's growth momentum will progress at a CAGR of 8.42%. Discover some insights on market size historic period (2017 to 2021) and forecast market data (2023 to 2027) before buying the full report -Request a sample report

Antithrombotic drugs market – Company Analysis

Company Landscape - The global antithrombotic drugs market is fragmented, with the presence of several global as well as regional vendors. A few prominent vendors that offer antithrombotic drugs in the market are AbbVie Inc., Aspen Pharmacare Holdings Ltd, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Johnson and Johnson Services Inc., Merck and Co. Inc., Novartis AG, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Fresenius Kabi AG and others.

What's New? -

• Special coverage on the Russia-Ukraine war; global inflation; recovery analysis from COVID-19; supply chain disruptions, global trade tensions; and risk of recession
• Global competitiveness and key competitor positions
• Market presence across multiple geographical footprints - Strong/Active/Niche/Trivial - Buy the report!

Company Offerings -

• Aspen Pharmacare Holdings Ltd - The company offers anti-thrombotic drugs such as Fraxiparine.
• AstraZeneca PLC - The company offers anti-thrombotic drugs and related solutions such as human recombinant apyrase therapy APT102 for the treatment of thrombotic diseases.
• Bayer AG - The company offers anti-thrombotic drugs such as Factor Xia inhibitors.
• For details on the vendor and their offerings – Request a sample report

Antithrombotic drugs market - Segmentation Assessment

Segment Overview

Technavio has segmented the market based on route of administration (oral and injectable), distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy), and geography (North America, Europe, Asia, and Rest of World (ROW)). 

• The oral segment will be significant during the forecast period. The growth of the segment can be attributed to the growing popularity of prescription-based drugs, such as oral capsules. In March 2023, Bristol Myers Squibb collaborated with Janssen Pharmaceuticals and announced the launch of the Phase 3 Librexia program studying milvexian, an investigational oral factor FXIa inhibitor for the antithrombotic drug. This drug can treat conditions associated with a thrombotic event and patient bleeding. Hence, such factors fuel the oral segment of the anti-thrombotic drugs market during the forecast period.

Geography Overview

By geography, the global antithrombotic drugs market is segmented into North America, Europe, Asia, and Rest of World (ROW). The report provides actionable insights and estimates the contribution of all regions to the growth of the global antithrombotic drugs market.

• North America will contribute 41% to the growth of the global market during the forecast period. The US and Canada are the leading revenue-generating countries in the regional market. The regional market growth can be attributed to factors such as the increasing awareness of the severity of diseases such as DVT and pulmonary embolism and the advanced healthcare system in the US. Furthermore, the regional market has many approved therapies, such as warfarin therapy and antiplatelet therapy. Hence, such factors drive the anti-thrombotic drugs market in North America during the forecast period.

For insights on global, regional, and country-level parameters with growth opportunities from 2017 to 2027 - Download a Sample Report

Antithrombotic drugs market – Market Dynamics

Leading Drivers - 

The growing prevalence of coagulation disorders drives the growth of the anti-thrombotic drugs market. Since people are leading unhealthy lifestyles that lack physical activities, there is a greater prevalence of cardiovascular disorders, kidney disorders, and strokes.

Furthermore, deep vein thrombosis and pulmonary embolism are two of the most common blood disorders globally. Such a condition is treated using antithrombotics. Hence, such factors drive the growth of the anti-thrombotic drugs market during the forecast period.

Key Trends - 

The advent of anticoagulant antidotes is an emerging anti-thrombotic drugs market trend. Although there is a high efficacy of oral anticoagulants in the treatment of thrombosis, the preference for oral anticoagulants is low. Numerous adverse side effects, such as bruising, prolonged nosebleeds, and vomiting blood is a major factor for this.

Furthermore, pharmaceutical players are researching antidotes for the treatment of thrombosis. Additionally, key vendors are expected to launch antidotes. Hence, such trends fuel the growth of the anti-thrombotic drugs market during the forecast period.

Major challenges - 

Strong side effects of anticoagulant drugs challenge the growth of the anti-thrombotic drugs market. Anticoagulants or blood thinners decrease the ability of blood to clot, thereby slowing down the blood clotting process, resulting in the flow of blood becoming uncontrollable.

Furthermore, some other side effects associated with using anticoagulants include severe bruising, prolonged nosebleeds, and vomiting blood. Hence, challenges like the rising awareness about the side effects of anticoagulants are expected to hinder the growth of the global antithrombotic drugs market during the forecast period.

Drivers, Trends, and Challenges have an impact on market dynamics, which can impact businesses. Find more insights in a sample report!

What are the key data covered in this antithrombotic drugs market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the antithrombotic drugs market between 2023 and 2027
• Precise estimation of the size of the antithrombotic drugs market and its contribution to the market with a focus on the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the antithrombotic drugs market across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of antithrombotic drugs market vendors

Gain instant access to 17,000+ market research reports. 

Technavio's SUBSCRIPTION platform

Related Reports:

The antidepressants drugs market size is expected to increase to USD 5.22 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.44%. Furthermore, this report extensively covers antidepressants drugs market segmentations by disease type (major compulsive disorder, obsessive compulsive disorder, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)). The rising prevalence of depression is notably driving the antidepressants drugs market growth.

The narcolepsy drugs market size is expected to increase to USD 1.60 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 9.1%. Furthermore, this report extensively covers narcolepsy drugs market segmentation by type (narcolepsy with cataplexy, narcolepsy without cataplexy, and secondary narcolepsy) and geography (North America, Europe, Asia, and Rest of World (ROW)). The rising product launches and clinical trials is notably driving the narcolepsy drugs market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
• Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.3 Market size 2022

• 3.4 Market outlook: Forecast for 2022-2027 
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global antithrombotic drugs market 2017 - 2021 
• Exhibit 18: Historic Market Size – Data Table on global antithrombotic drugs market 2017 - 2021 ($ million)

• 4.2 Route of Administration Segment Analysis 2017 - 2021 
• Exhibit 19: Historic Market Size – Route of Administration Segment 2017 - 2021 ($ million)

• 4.3 Distribution Channel Segment Analysis 2017 - 2021 
• Exhibit 20: Historic Market Size – Distribution Channel Segment 2017 - 2021 ($ million)

• 4.4 Geography Segment Analysis 2017 - 2021 
• Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)

• 4.5 Country Segment Analysis 2017 - 2021 
• Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

• 5.2 Bargaining power of buyers 
• Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 5.3 Bargaining power of suppliers 
• Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 5.4 Threat of new entrants 
• Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

• 5.5 Threat of substitutes 
• Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Route of Administration

• 6.1 Market segments
• Exhibit 30: Chart on Route of Administration - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Route of Administration - Market share 2022-2027 (%)

• 6.2 Comparison by Route of Administration 
• Exhibit 32: Chart on Comparison by Route of Administration
• Exhibit 33: Data Table on Comparison by Route of Administration

• 6.3 Oral - Market size and forecast 2022-2027 
• Exhibit 34: Chart on Oral - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Oral - Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Oral - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Oral - Year-over-year growth 2022-2027 (%)

• 6.4 Injectable - Market size and forecast 2022-2027 
• Exhibit 38: Chart on Injectable - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on Injectable - Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on Injectable - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Injectable - Year-over-year growth 2022-2027 (%)

• 6.5 Market opportunity by Route of Administration 
• Exhibit 42: Market opportunity by Route of Administration ($ million)
• Exhibit 43: Data Table on Market opportunity by Route of Administration ($ million)

7 Market Segmentation by Distribution Channel

• 7.1 Market segments
• Exhibit 44: Chart on Distribution Channel - Market share 2022-2027 (%)
• Exhibit 45: Data Table on Distribution Channel - Market share 2022-2027 (%)

• 7.2 Comparison by Distribution Channel 
• Exhibit 46: Chart on Comparison by Distribution Channel
• Exhibit 47: Data Table on Comparison by Distribution Channel

• 7.3 Hospital pharmacy - Market size and forecast 2022-2027 
• Exhibit 48: Chart on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 49: Data Table on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 50: Chart on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibit 51: Data Table on Hospital pharmacy - Year-over-year growth 2022-2027 (%)

• 7.4 Retail pharmacy - Market size and forecast 2022-2027 
• Exhibit 52: Chart on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 53: Data Table on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 54: Chart on Retail pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibit 55: Data Table on Retail pharmacy - Year-over-year growth 2022-2027 (%)

• 7.5 Online pharmacy - Market size and forecast 2022-2027 
• Exhibit 56: Chart on Online pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 57: Data Table on Online pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 58: Chart on Online pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibit 59: Data Table on Online pharmacy - Year-over-year growth 2022-2027 (%)

• 7.6 Market opportunity by Distribution Channel 
• Exhibit 60: Market opportunity by Distribution Channel ($ million)
• Exhibit 61: Data Table on Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview 
• Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation 
• Exhibit 63: Chart on Market share by geography 2022-2027 (%)
• Exhibit 64: Data Table on Market share by geography 2022-2027 (%)

• 9.2 Geographic comparison 
• Exhibit 65: Chart on Geographic comparison
• Exhibit 66: Data Table on Geographic comparison

• 9.3 North America - Market size and forecast 2022-2027 
• Exhibit 67: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 68: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 69: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 70: Data Table on North America - Year-over-year growth 2022-2027 (%)

• 9.4 Europe - Market size and forecast 2022-2027 
• Exhibit 71: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 72: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 73: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 74: Data Table on Europe - Year-over-year growth 2022-2027 (%)

• 9.5 Asia - Market size and forecast 2022-2027 
• Exhibit 75: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 76: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 77: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 78: Data Table on Asia - Year-over-year growth 2022-2027 (%)

• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 
• Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

• 9.7 US - Market size and forecast 2022-2027 
• Exhibit 83: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 84: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 85: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 86: Data Table on US - Year-over-year growth 2022-2027 (%)

• 9.8 Germany - Market size and forecast 2022-2027 
• Exhibit 87: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 88: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 89: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 90: Data Table on Germany - Year-over-year growth 2022-2027 (%)

• 9.9 UK - Market size and forecast 2022-2027 
• Exhibit 91: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 92: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 93: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 94: Data Table on UK - Year-over-year growth 2022-2027 (%)

• 9.10 Japan - Market size and forecast 2022-2027 
• Exhibit 95: Chart on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 96: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 97: Chart on Japan - Year-over-year growth 2022-2027 (%)
• Exhibit 98: Data Table on Japan - Year-over-year growth 2022-2027 (%)

• 9.11 Canada - Market size and forecast 2022-2027 
• Exhibit 99: Chart on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 100: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 101: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibit 102: Data Table on Canada - Year-over-year growth 2022-2027 (%)

• 9.12 Market opportunity by geography 
• Exhibit 103: Market opportunity by geography ($ million)
• Exhibit 104: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers

• 10.2 Market challenges

• 10.3 Impact of drivers and challenges 
• Exhibit 105: Impact of drivers and challenges in 2022 and 2027

• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview

• 11.2 Vendor landscape
• Exhibit 106: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption
• Exhibit 107: Overview on factors of disruption

• 11.4 Industry risks
• Exhibit 108: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 109: Vendors covered

• 12.2 Market positioning of vendors 
• Exhibit 110: Matrix on vendor position and classification

• 12.3 Aspen Pharmacare Holdings Ltd 
• Exhibit 111: Aspen Pharmacare Holdings Ltd - Overview
• Exhibit 112: Aspen Pharmacare Holdings Ltd - Business segments
• Exhibit 113: Aspen Pharmacare Holdings Ltd - Key offerings
• Exhibit 114: Aspen Pharmacare Holdings Ltd - Segment focus

• 12.4 AstraZeneca PLC
• Exhibit 115: AstraZeneca PLC - Overview
• Exhibit 116: AstraZeneca PLC - Product / Service
• Exhibit 117: AstraZeneca PLC - Key news
• Exhibit 118: AstraZeneca PLC - Key offerings

• 12.5 Bayer AG
• Exhibit 119: Bayer AG - Overview
• Exhibit 120: Bayer AG - Business segments
• Exhibit 121: Bayer AG - Key news
• Exhibit 122: Bayer AG - Key offerings
• Exhibit 123: Bayer AG - Segment focus

• 12.6 Boehringer Ingelheim International GmbH 
• Exhibit 124: Boehringer Ingelheim International GmbH - Overview
• Exhibit 125: Boehringer Ingelheim International GmbH - Business segments
• Exhibit 126: Boehringer Ingelheim International GmbH - Key news
• Exhibit 127: Boehringer Ingelheim International GmbH - Key offerings
• Exhibit 128: Boehringer Ingelheim International GmbH - Segment focus

• 12.7 Bristol Myers Squibb Co. 
• Exhibit 129: Bristol Myers Squibb Co. - Overview
• Exhibit 130: Bristol Myers Squibb Co. - Product / Service
• Exhibit 131: Bristol Myers Squibb Co. - Key news
• Exhibit 132: Bristol Myers Squibb Co. - Key offerings

• 12.8 Daiichi Sankyo Co. Ltd. 
• Exhibit 133: Daiichi Sankyo Co. Ltd. - Overview
• Exhibit 134: Daiichi Sankyo Co. Ltd. - Product / Service
• Exhibit 135: Daiichi Sankyo Co. Ltd. - Key news
• Exhibit 136: Daiichi Sankyo Co. Ltd. - Key offerings

• 12.9 Eli Lilly and Co.
• Exhibit 137: Eli Lilly and Co. - Overview
• Exhibit 138: Eli Lilly and Co. - Product / Service
• Exhibit 139: Eli Lilly and Co. - Key news
• Exhibit 140: Eli Lilly and Co. - Key offerings

• 12.10 F. Hoffmann La Roche Ltd. 
• Exhibit 141: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 142: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 143: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 144: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 145: F. Hoffmann La Roche Ltd. - Segment focus

• 12.11 Fresenius Kabi AG
• Exhibit 146: Fresenius Kabi AG - Overview
• Exhibit 147: Fresenius Kabi AG - Business segments
• Exhibit 148: Fresenius Kabi AG - Key news
• Exhibit 149: Fresenius Kabi AG - Key offerings
• Exhibit 150: Fresenius Kabi AG - Segment focus

• 12.12 Hikma Pharmaceuticals Plc 
• Exhibit 151: Hikma Pharmaceuticals Plc - Overview
• Exhibit 152: Hikma Pharmaceuticals Plc - Business segments
• Exhibit 153: Hikma Pharmaceuticals Plc - Key offerings
• Exhibit 154: Hikma Pharmaceuticals Plc - Segment focus

• 12.13 Novartis AG
• Exhibit 155: Novartis AG - Overview
• Exhibit 156: Novartis AG - Business segments
• Exhibit 157: Novartis AG - Key offerings
• Exhibit 158: Novartis AG - Segment focus

• 12.14 Otsuka Pharmaceutical Co. Ltd. 
• Exhibit 159: Otsuka Pharmaceutical Co. Ltd. - Overview
• Exhibit 160: Otsuka Pharmaceutical Co. Ltd. - Product / Service
• Exhibit 161: Otsuka Pharmaceutical Co. Ltd. - Key offerings

• 12.15 Sanofi SA
• Exhibit 162: Sanofi SA - Overview
• Exhibit 163: Sanofi SA - Business segments
• Exhibit 164: Sanofi SA - Key news
• Exhibit 165: Sanofi SA - Key offerings
• Exhibit 166: Sanofi SA - Segment focus

• 12.16 Teva Pharmaceutical Industries Ltd. 
• Exhibit 167: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 168: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 169: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 170: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 171: Teva Pharmaceutical Industries Ltd. - Segment focus

• 12.17 Viatris Inc.
• Exhibit 172: Viatris Inc. - Overview
• Exhibit 173: Viatris Inc. - Business segments
• Exhibit 174: Viatris Inc. - Key news
• Exhibit 175: Viatris Inc. - Key offerings
• Exhibit 176: Viatris Inc. - Segment focus

13 Appendix

• 13.1 Scope of the report

• 13.2 Inclusions and exclusions checklist 
• Exhibit 177: Inclusions checklist
• Exhibit 178: Exclusions checklist

• 13.3 Currency conversion rates for US$ 
• Exhibit 179: Currency conversion rates for US$

• 13.4 Research methodology
• Exhibit 180: Research methodology
• Exhibit 181: Validation techniques employed for market sizing
• Exhibit 182: Information sources

• 13.5 List of abbreviations 
• Exhibit 183: List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com

SOURCE Technavio